Sharing session - The Three Tips

The fight against macular degeneration is often a lonely process. But it gets better when you are able to pick the brains of others on how to cope. And in our view, the greatest treasure trove of information lies within us - the members of MDS. Come join us in a sharing session among members on your three best tips to live with macular degeneration.

There is no right or wrong answer. There is no good or bad answer too. Your tips can be on anything, ranging from medicinal to exercises, from technology to household changes, from how to connect with a doctor to the best way to get back home after a check-up. In short, it can be on ANYTHING.

What we take for granted in our own struggles with macular degeneration is very likely not familiar to others. And it could make a big difference in all our lives when we share and pick up these unknown "personal strategies".

Date: Feb 11, 2012 (Sat)
Time: 2pm - 4pm
Venue: All For Eyes shop, Tanglin Shopping Centre, 19 Tanglin Road, #05-23, Spore 247909

 Call Anne at 6238-7387, or e-mail alleyes@singnet.com.sg to reserve your places now for our first event of 2012!

This event is free for all MDS members. If you know of someone who you feel might benefit from joining our circle, please invite them, just let us know in advance.

REMINDER for members, please arrange to pay your membership fees ($20 for 2 years) if you haven't done so.

Stem cell retinal implants safe

Early results from the world's first human trial using embryonic stem cells to treat diseases of the eye suggest the method is safe, say researchers. US firm Advanced Cell Technology told The Lancet how two patients who had received the retinal implants were doing well, four months on.

Trials of the same technique have now started at London's Moorfields Eye Hospital. But experts say it will be years before these treatments are proven. The aim of these first human studies is to establish that the treatment is safe to use. 

Click here to read the full BBC story. More details here from Reuters.